In the News

Popular ScienceArticleScientists reworked an experimental cancer therapy to treat autoimmune disease
EndpointsArticleCAR-T cell therapy for myasthenia gravis shows promise in small study by Cartesian Therapeutics
The EconomistArticleA risky cancer treatment can be modified to treat immune diseases
BioBuzzArticle Cartesian Therapeutics kicks off Phase IIb study of rCAR-T in autoimmune disease
StatnewsArticle Cartesian welcomes Chris Jewell as Chief Scientific Officer
Inside Precision MedicineArticleConfronting Challenges in Developing Cell and Gene Therapies
Evaluate VantageArticleCartesian maps the path for an autoimmune disease cell therapy
National Institute of HealthPress releasePotential treatment for rare autoimmune disorder adapted from CAR-T therapy
European Pharmaceutical ReviewArticleFirst RNA CAR-T therapy autoimmunity trial shows potential
Inside Precision MedicineArticleCAR-T Adaptation Could Treat Myasthenia Gravis
The Science Advisory BoardArticlePotential treatment for rare autoimmune disorder adapted from CAR-T therapy in study
RegMedNetArticleCell therapy weekly: US FDA priority review for Biologics License Application for sickle cell disease gene therapy
ForbesArticleThe Future Of Cancer Treatment? Treating Multiple Myeloma With MRNA-CAR T Technology
Hospital Healthcare EuropeArticleRNA CAR T therapy offers hope for patients with myasthenia gravis
Myasthenia Gravis NewsArticleDescartes-08, novel CAR T-cell therapy, shows promise in gMG
CBS17Broadcast NC man sees big improvement in autoimmune disease after experimental treatment at UNC
Precision Medicine OnlineArticleCartesian Therapeutics Advancing RNA-Based CAR-T in Myasthenia Gravis After Promising Early Data
Medpage TodayArticleAdapted CAR-T Therapy Shows Promise in Myasthenia Gravis — Proof-of-concept study suggests RNA-engineered cells may be less toxic
Neurology TodayArticleNovel Approach to CAR T-Cell Therapy Shows Early Promise in Myasthenia Gravis
Mgfa Blog Article Can Cart T-Cell Therapy Effectively Treat Myasthenia Gravis?
DocWire NewsVideo InterviewDr. Murat Kalayoglu, President & CEO, Cartesian Therapeutics: The Leader in RNA Cell Therapy
Cell & GenePodcastMoving To An Allogeneic RNA Cell Therapy Program With Cartesian Therapeutics’ Dr. Metin Kurtoglu
Cell & GeneWebinarAdvancements In Targeted mRNA Delivery
Myasthenia Gravis NewsArticle CAR T-cell Therapy Descartes-08 Continues to Show Promise in Trial
BioCenturyArticleCartesian expanding therapeutic window, disease settings for CAR T
Maryland Tech CouncilAwardMaryland Tech Council Unveils Winners of 34th Annual Industry Awards
CGT LiveArticleRNA CAR T-Cell Therapy for Myasthenia Gravis Shows Benefits in Early Results
Cell & Gene Therapy InsightsArticleUnleashing the full potential of cell therapy through RNA engineering
Washington Business JournalArticleCompanies to watch: 6 life sciences leaders see Montgomery County as partner in success
BioTuesdaysArticleIn conversation with Dr. Murat Kalayoglu of Cartesian
BioSpectrum AsiaArticleExploring the Possibilities of RNA Therapeutics
Science LineArticleThe mRNA revolution is just getting started
The Daily RecordArticleMd. Tech Council announces 2022 Industry Awards finalists
CGT LiveArticleAdvancing Treatments for Rare Diseases Requires a Team Approach
BioSpaceArticleCartesian Aims to Propel RNA Cell Therapy with Combinations
Cell & GenePodcastRNA’s Advantages Over Other Cell Therapies With Cartesian’s CSO
Biopharma ReporterArticleCartesian Therapeutics: Senior Advisors
PharmaShotsArticlePharmaShots Interview: Cartesian Therapeutics’s Dr. Murat Kalayoglu Shares Insight on RNA Cell Therapy for an Autoimmune Disease
Washington Business JournalArticleGaithersburg is evolving gradually, with several new projects in the works. Join us on a tour.
Technology NetworksArticleInnovating Reversible Cell Therapies With RNA
Pharmaceutical ExecutiveArticleThe New COVID Workforce: Keeping Pharma Strong Through Adversity
DNAweeklyArticleExploring RNA-Based Oncology Treatments With Cartesian Therapeutics
BioSpaceArticleCarting Away Problematic Cells with CAR-T Therapy for Myasthenia Gravis

GENArticleBuilding a Bioprocess for RNA-Based Therapies
Fierce BiotechBriefChutes & Ladders—FDA’s vaccine office gets new leader as 2 officials head toward exit
BioSpaceBriefBioSpace Movers & Shakers, Oct. 1
PharmTech FocusArticleCartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer
Washington Business JournalArticleGaithersburg biopharma prepares to double footprint, headcount
BioWorldBriefAppointments and advancements for Sept. 28, 2021
Gene Therapy LiveVideoRNA-Modified vs DNA-Modified CAR T Products
Myasthenia Gravis NewsArticleCAR T-cell Therapy Descartes-08 Eased MG Symptoms
Cell & GenePodcastState-of-the-Art GMP Manufacturing RNA Cell Therapies With Cartesian’s CEO
Life Science LeaderArticleImplementing GMP For Early-Phase Development With Cartesian Therapeutics Co-Founder And CEO, Dr. Murat Kalayoglu
Clinical LeaderArticleNo CMOs Or CROs: A Unique Approach To Cell Therapy Development
RARECASTPodcastEpisode #342 – Overcoming the Limitations of Conventional Cell Engineering
BioProcess OnlineArticleGMP Manufacturing Of RNA-Engineered Cell Therapies
BioTalkPodcastMurat Kalayoglu, MD, PhD – Cartesian Therapeutics (EP.89)
Clinical Trials ArenaArticleCartesian: pioneering RNA-engineered cell therapy in cancer and beyond
Contagion LiveArticle + VideoRNA Cell Therapy for COVID-19 Related ARDS in Development
Business of BiotechPodcastRNA-Engineered Cell Therapy With Cartesian’s Dr. Murat Kalayoglu
Cell & GeneArticleRNA Cell Therapy: A New Class of Advanced Therapies
Health Professional RadioPodcastCartesian-Therapeutics-–-Pioneering-mRNA-Engineered-Cell-Therapy
HealioArticleThe case for CAR T cells as earlier treatment requires more evidence
GENPanelCAR-T Therapy: Working with a Manufacturing Partner
InformaPanelPandemic Perspectives: R&D Lessons Learned from the COVID Year
DocWire NewsVideo InterviewDr. Murat Kalayoglu Discusses New Frontline Therapy Treatment for Multiple Myeloma
OncLiveArticlemRNA-Based CAR T-Cell Therapy Descartes-11 Moves Into Phase 2 Trial in Myeloma
Cancer Therapy AdvisorArticleDescartes-11 Trial Tests RNA-Engineer Cell Therapy in Multiple Myeloma
Precision Oncology NewsArticleCartesian Therapeutics Bets on mRNA Engineering for Moving CAR T Cells Into Frontline Treatment
CUREArticleCartesian Therapeutics Bets on mRNA Engineering for Moving CAR T Cells Into Frontline Treatment
Scroll to Top